TIF
Issue 62 – March 2013
Latest News:
- GBT Announces Plans to Seek Regulatory Approval for Oxbryta® (Voxelotor) to Treat Sickle Cell Patients in Europe
- Thalassaemia Prior and Consequent to COVID-19 Pandemic: The Perspective of Thalassaemia International Federation (TIF)
- IMR-687 Receives FDA Orphan Drug Designation for the Treatment of β-Τhalassaemia
- European Commission Approves Reblozyl for the Treatment of Transfusion-dependent β-Thalassaemia
- 25th EHA Annual Virtual Congress: TIF Brings you All the Latest Developments on Thalassaemia
